Serum chemerin levels are associated with the presence and extent of coronary artery disease.
ABSTRACT The aim of the study was to examine whether serum chemerin levels are associated with the presence and the extent of coronary artery disease (CAD).
A total of 132 patients with CAD and 56 patients without CAD who underwent coronary angiography for the evaluation of CAD were enrolled in this study. Serum levels of chemerin were measured using an enzyme-linked immunosorbent assay.
Serum chemerin levels were significantly elevated in CAD patients compared with those without CAD. Multivariate logistic regression analysis showed that serum chemerin levels were significantly associated with the presence of CAD. In CAD patients, chemerin was positively correlated with BMI (r=0.274, P=0.001) and triglycerides (r=0.190, P=0.029), and yet correlated with low-density lipoprotein-cholesterol (r=0.228, P=0.008); the association of chemerin with triglycerides and low-density lipoprotein-cholesterol remained significant after adjusting for BMI (P<0.05 and P<0.01). At multiple stepwise regression analysis, serum chemerin levels were an independent predictor of the stenosis score (β=0.193, P=0.034).
Our data suggest that increased chemerin levels are associated with the presence of CAD and that serum chemerin levels may reflect the extent of coronary atherosclerosis.
- SourceAvailable from: PubMed Central[Show abstract] [Hide abstract]
ABSTRACT: Background Recent evidence demonstrated that the circulating adipokines were associated with the onset of acute coronary syndrome (ACS) including unstable angina pectoris (UAP) and acute myocardial infarction (AMI). As a novel adipokine, chemerin has been related to atherosclerosis and the presence of coronary artery disease. However, the plasma levels of chemerin in patients with ACS have yet to be investigated.Methods Plasma levels of chemerin and adiponectin were measured by an enzyme-linked immunosorbent assay (ELISA) in 60 patients with stable angina pectoris (SAP), 60 patients with UAP, 60 patients with AMI and 40 control patients. Left ventricular end-diastolic diameter (LVEDD) and left ventricular ejection fraction (LVEF) were measured using a GE ViVid E7 ultrasonography machine, and the severity of coronary stenosis in patients was estimated with a Gensini coronary score following coronary angiography.ResultsPlasma chemerin levels were significantly higher in ACS patients than in the control and SAP groups, while plasma adiponectin levels were significantly lower in ACS patients than the control group. A correlation analysis revealed that plasma chemerin levels were positively correlated with the levels of C-reactive protein (CRP) (r¿=¿0.29, P¿<¿0.01) and LVEDD (r¿=¿0.27, P¿<¿0.01) but negatively correlated with LVEF (r¿=¿-0.45, P¿<¿0.01) and that plasma adiponectin levels were positively correlated with LVEF (r¿=¿0.53, P¿<¿0.01) but negatively correlated with CRP (r¿=¿-0.33, P¿<¿0.01) and LVEDD (r¿=¿-0.30, P¿<¿0.01). Although significant correlations between chemerin, adiponectin and BMI or the Gensini coronary score were found in patients with SAP, neither chemerin nor adiponectin was correlated with BMI and the Gensini coronary score in patients with ACS. Furthermore, both chemerin (OR 1.103, 95% CI 1.065 to 1.142; P¿=¿0.001) and adiponectin (OR 0.871, 95% CI 0.776 to 0.970; P¿=¿0.018) were independently associated with the presence of ACS.Conclusions Chemerin is a novel biomarker of acute coronary syndrome but not of stable angina pectoris.Cardiovascular Diabetology 11/2014; 13(1):145. · 4.21 Impact Factor
- [Show abstract] [Hide abstract]
ABSTRACT: Chemerin is a peptide chemoattractant for macrophages and an adipokine regulating adipocyte differentiation and metabolism. Plasma chemerin is increased in chronic inflammatory diseases and in obesity. As inflammation and obesity are risk factors for coronary artery disease (CAD), we investigated possible associations of plasma chemerin with inflammatory markers and atherosclerosis in a CAD case-control study (n=470). Chemerin levels were associated with C-reactive protein, BMI and LDL levels, and negatively associated with HDL levels. Mean plasma chemerin levels were similar in controls and CAD patients but significantly higher in CAD patients not taking low dose aspirin. To investigate the mechanism of chemerin reduction by aspirin, we analyzed chemerin expression in hepatocytes and adipocytes treated with aspirin in the presence and absence of inflammatory cytokines. Chemerin expression was upregulated by pro-inflammatory stimuli in adipocytes but not in hepatocytes. Treatment of stimulated hepatocytes and adipocytes with aspirin did not affect chemerin expression. However, treatment of inflammatory M1 macrophages with aspirin reduced secretion of the pro-inflammatory cytokines IL-1β and IL-6, and increased secretion of the anti-inflammatory IL-10. In summary, we show that plasma chemerin levels are associated with markers of inflammation and that they are significantly higher in CAD patients not treated with low dose aspirin. In addition, we show that low dose aspirin treatment reduces pro-inflammatory cytokine secretion by macrophages, which may lead to reduced chemerin secretion by adipocytes and may be a reason for the lower chemerin levels in the circulation of CAD patients on low dose aspirin.Atherosclerosis 05/2014; 235(2):256-262. · 3.71 Impact Factor
- [Show abstract] [Hide abstract]
ABSTRACT: Coronary artery disease (CAD) is associated with abdominal obesity and metabolic syndrome. Adipocytes secrete adipokines, including the newly discovered adipocyte fatty acid binding protein (A-FABP) and chemerin. Adipokines contribute to the pathogenesis of CAD. In patients with CAD, the presence of significant ischemia predicts adverse outcomes. It is unknown whether adipokines can be better predictors of the presence of significant myocardial ischemia than conventional risk factors. This study aimed to compare adipokines with clinical risk factors and abdominal obesity as predictive factors for significant myocardial ischemia.PLoS ONE 01/2014; 9(5):e97710. · 3.53 Impact Factor